End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
9.93 USD | -3.03% | +4.64% | +17.51% |
Financials (USD)
Sales 2024 * | 30.64M | Sales 2025 * | 48.29M | Capitalization | 250M |
---|---|---|---|---|---|
Net income 2024 * | -36M | Net income 2025 * | -29M | EV / Sales 2024 * | 8.16 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 5.18 x |
P/E ratio 2024 * |
-4.33
x | P/E ratio 2025 * |
-6.32
x | Employees | 112 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 45.1% |
Latest transcript on TriSalus Life Sciences, Inc.
1 day | -3.03% | ||
1 week | +4.64% | ||
Current month | +1.85% | ||
1 month | +6.55% | ||
3 months | +9.12% | ||
6 months | +109.05% | ||
Current year | +17.51% |
Managers | Title | Age | Since |
---|---|---|---|
Mary Szela
CEO | Chief Executive Officer | 61 | 17-12-31 |
Sean Murphy
DFI | Director of Finance/CFO | 71 | 23-08-09 |
Steven Katz
CTO | Chief Tech/Sci/R&D Officer | 49 | 23-08-09 |
Members of the board | Title | Age | Since |
---|---|---|---|
Kerry Hicks
BRD | Director/Board Member | 64 | 23-08-09 |
Mats Wahlström
CHM | Chairman | 70 | 23-08-09 |
George Martin
BRD | Director/Board Member | 65 | 23-08-09 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 9.35 | -5.84% | 205,822 |
24-04-25 | 9.93 | -3.03% | 345,524 |
24-04-24 | 10.24 | +0.39% | 15,607 |
24-04-23 | 10.2 | +3.66% | 47,472 |
24-04-22 | 9.84 | +3.69% | 10,585 |
End-of-day quote Nasdaq, April 24, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.51% | 250M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- TLSI Stock